Varespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations.

Varespladib (LY315920) is a synthetic phospholipase A 2 (PLA 2) inhibitor that has been demonstrating antiophidic potential against snake venoms that present PLA 2 neurotoxins. In this study, we evaluate the capacity of Varespladib to inhibit the neuromuscular effects of crotoxin (CTX), the main toxic component of Crotalus durissus terrificus snake venom, and its PLA 2 subunit (CB). We performed a myographic study to compare the neuromuscular effects of CTX or CB and the mixture of these substances plus Varespladib in mice phrenic nerve-diaphragm muscle preparations. CTX (5 μg/mL), CB (20 μg/mL), or toxin-inhibitor mixtures pre-incubated with different concentration ratios of Varespladib (1:0.25; 1:0.5; 1:1; w/w) were added to the preparations and maintained throughout the experimentation period. Myotoxicity was assessed by light microscopic analysis of diaphragm muscle after myographic study. CTX and CB blocked the nerve-evoked twitches, and only CTX induced histological alterations in diaphragm muscle. Pre-incubation with Varespladib abolished the muscle-paralyzing activity of CTX and CB, and also the muscle-damaging activity of CTX. These findings emphasize the clinical potential of Varespladib in mitigating the toxic effects of C. d. terrificus snakebites and as a research tool to advance the knowledge of the mechanism of action of snake toxins. • Crotoxin and CB induce a time-dependent blockade of ex vivo neuromuscular preparations. • Crotoxin promotes myotoxicity in mice diaphragm muscle. • Varespladib prevents the neuromuscular blockade induced by Crotoxin and CB. • Varespladib neutralizes the myotoxicity of CTX. • Varespladib is an important tool for the study of snake PLA 2 toxins. [ABSTRACT FROM AUTHOR]